240 related articles for article (PubMed ID: 7531941)
1. Sterility of unit dose syringes of filgrastim and sargramostim.
Singh RF; Corelli RL; Guglielmo BJ
Am J Hosp Pharm; 1994 Nov; 51(22):2811-2. PubMed ID: 7531941
[No Abstract] [Full Text] [Related]
2. Sterility of repackaged filgrastim and sargramostim.
Kleinberg ML
Am J Health Syst Pharm; 1995 May; 52(10):1101. PubMed ID: 7544685
[No Abstract] [Full Text] [Related]
3. Comment: filgrastim sterility in syringes.
Trissel LA; Spadoni VT
Ann Pharmacother; 1997 Apr; 31(4):500-1. PubMed ID: 9101020
[No Abstract] [Full Text] [Related]
4. Drug formulary review process for sargramostim and filgrastim: focus on analysis of adverse drug reactions.
Kellihan MJ
Clin Ther; 1993; 15(5):927-37. PubMed ID: 7505717
[TBL] [Abstract][Full Text] [Related]
5. Clinical effects of biologic response modifiers.
Louie SG; Jung B
Am J Hosp Pharm; 1993 Jul; 50(7 Suppl 3):S10-8. PubMed ID: 7689788
[TBL] [Abstract][Full Text] [Related]
6. Immediate hypersensitivity to human recombinant granulocyte-macrophage colony-stimulating factor associated with a positive prick skin test reaction.
Engler RJ; Weiss RB
Ann Allergy Asthma Immunol; 1996 Jun; 76(6):531-4. PubMed ID: 8673688
[TBL] [Abstract][Full Text] [Related]
7. Sterility of filgrastim (G-CSF) in syringes.
Jacobson PA; West NJ; Spadoni V; Maksym CJ; Pierson C
Ann Pharmacother; 1996 Nov; 30(11):1238-42. PubMed ID: 8913403
[TBL] [Abstract][Full Text] [Related]
8. Big cost savings from small filgrastim unit doses.
Sinsabaugh DK; Freyer DR
Am J Hosp Pharm; 1993 Jul; 50(7):1363-4. PubMed ID: 7689787
[No Abstract] [Full Text] [Related]
9. Cost considerations in therapy with myeloid growth factors.
Glaspy JA; Jakway J
Am J Hosp Pharm; 1993 Jul; 50(7 Suppl 3):S19-26. PubMed ID: 7689789
[TBL] [Abstract][Full Text] [Related]
10. [Colony stimulating factors in blood formation].
Goebel M
Infusionsther Transfusionsmed; 1994 Nov; 21 Suppl 3():51-6. PubMed ID: 7531048
[TBL] [Abstract][Full Text] [Related]
11. Effect of granulocyte-macrophage colony stimulating factor and granulocyte colony stimulating factor on prolactin and adrenocorticotropic hormone secretion in rats: dose- and time-response in vivo studies.
Komorowski J; Zylińska K; Mucha S; Robak T; Wrzesien-Kus A; Stepień H
Cytobios; 1996; 86(346):147-53. PubMed ID: 9022262
[TBL] [Abstract][Full Text] [Related]
12. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.
Kopf B; De Giorgi U; Vertogen B; Monti G; Molinari A; Turci D; Dazzi C; Leoni M; Tienghi A; Cariello A; Argnani M; Frassineti L; Scarpi E; Rosti G; Marangolo M
Bone Marrow Transplant; 2006 Sep; 38(6):407-12. PubMed ID: 16951690
[TBL] [Abstract][Full Text] [Related]
13. Filgrastim post-chemotherapy mobilizes more CD34+ cells compared to its use during steady-state haemopoiesis.
Perez-Oteyza J; Garcia-Laraña J; Ramos P; Zamora C; Lopez-Jimenez J; Roldan E; Odriozola J
Bone Marrow Transplant; 1995 Aug; 16(2):324-5. PubMed ID: 7581160
[No Abstract] [Full Text] [Related]
14. Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer.
Kennedy MJ; Davis J; Passos-Coelho J; Noga SJ; Huelskamp AM; Ohly K; Davidson NE
Cancer Res; 1993 Nov; 53(22):5424-8. PubMed ID: 7693341
[TBL] [Abstract][Full Text] [Related]
15. Getting the most out of low-dose syringe prefilling of a high-cost biotechnology agent.
Lu A; Chan L
Hosp Pharm; 1994 Apr; 29(4):353, 356-7. PubMed ID: 10133464
[TBL] [Abstract][Full Text] [Related]
16. Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency.
Nissen C
Eur J Cancer; 1994; 30A Suppl 3():S12-4. PubMed ID: 7535065
[TBL] [Abstract][Full Text] [Related]
17. The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial.
Skowron G; Stein D; Drusano G; Melbourne K; Bilello J; Mikolich D; Rana K; Agosti JM; Mongillo A; Whitmore J; Gilbert MJ
J Infect Dis; 1999 Oct; 180(4):1064-71. PubMed ID: 10479132
[TBL] [Abstract][Full Text] [Related]
18. Quality control guidelines for single unit packaging of parenterals in the hospital pharmacy.
Patel JA; Curtis EG; Phillips GL
Am J Hosp Pharm; 1972 Nov; 29(11):947-51. PubMed ID: 4655003
[No Abstract] [Full Text] [Related]
19. Granulocyte colony-stimulating factor administration and monocyte phenotype.
Ohsaka A
Exp Hematol; 1996 Jun; 24(7):767. PubMed ID: 8647225
[No Abstract] [Full Text] [Related]
20. Peripheral blood mononuclear mobilization with sargramostim (GM-CSF).
Ahmed T; Preti RA; Razis E; Farley T; Lake DE; Beer M; Cook P; Ciavarella D
Prog Clin Biol Res; 1994; 389():457-62. PubMed ID: 7535454
[No Abstract] [Full Text] [Related]
[Next] [New Search]
